Clinical trial
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
NCT00275041 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00275041 |
|---|---|
| Title | Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of Concurrent Irinotecan Plus Cetuximab in Patients With Advanced Breast Cancer With Prior Anthracycline and/or Taxane-Containing Therapy |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, irinotecan hydrochloride |
| Enrollment | 21 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Jan 11, 2006 |
| Last update posted | Dec 13, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: